2026-04-17T05:42:04Zhttps://recercat.cat/oai/request

oai:recercat.cat:10256/142512024-06-14T10:33:27Zcom_2072_452955com_2072_2054col_2072_453079

Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus Sepúlveda, Maria Armangué, Thaís Sola Valls, Nuria Arrambide, Georgina Meca Lallana, José E. Oreja-Guevara, Celia Mendibe, Mar Alvarez de Arcaya, Amaya Aladro, Yolanda Casanova Estruch, Bonaventura Olascoaga, Javier Jiménez Huete, Adolfo Fernández Fournier, Mireya Ramió i Torrentà, Lluís Cobo Calvo, Alvaro Viñals, Montserrat Andrés, Clara de Meca Lallana, Virginia Cervelló, Angeles Calles, Carmen Barón Rubio, Manuel Ramo Tello, Cristina Caminero, Ana Munteis, Elvira Antigüedad, Alfredo R. Blanco, Yolanda Villoslada, Pablo Montalban Gairín, Xavier Graus, Francesc Saiz, Albert NMO Study Group Nervi òptic -- Malalties Optic nerve -- Diseases Nervis perifèrics -- Malalties Nerves, Peripheral -- Diseases To (1) determine the value of the recently proposed criteria of neuromyelitis optica (NMO) spectrum disorder (NMOSD) that unify patients with NMO and those with limited forms (NMO/LF) with aquaporin-4 immunoglobulin G (AQP4-IgG) antibodies; and (2) investigate the clinical significance of the serologic status in patients with NMO.This was a retrospective, multicenter study of 181 patients fulfilling the 2006 NMO criteria (n = 127) or NMO/LF criteria with AQP4-IgG (n = 54). AQP4-IgG and myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) antibodies were tested using cell-based assays.Patients were mainly white (86%) and female (ratio 6.5:1) with median age at onset 39 years (range 10-77). Compared to patients with NMO and AQP4-IgG (n = 94), those with NMO/LF presented more often with longitudinally extensive transverse myelitis (LETM) (p < 0.001), and had lower relapse rates (p = 0.015), but similar disability outcomes. Nonwhite ethnicity and optic neuritis presentation doubled the risk for developing NMO compared with white race (p = 0.008) or LETM presentation (p = 0.008). Nonwhite race (hazard ratio [HR] 4.3, 95% confidence interval [CI] 1.4-13.6) and older age at onset were associated with worse outcome (for every 10-year increase, HR 1.7, 95% CI 1.3-2.2). Patients with NMO and MOG-IgG (n = 9) had lower female:male ratio (0.8:1) and better disability outcome than AQP4-IgG-seropositive or double-seronegative patients (p < 0.001).In patients with AQP4-IgG, the similar outcomes regardless of the clinical phenotype support the unified term NMOSD; nonwhite ethnicity and older age at onset are associated with worse outcome. Double-seronegative and AQP4-IgG-seropositive NMO have a similar clinical outcome. The better prognosis of patients with MOG-IgG and NMO suggests that phenotypic and serologic classification is useful This study was supported in part by Red Española de Esclerosis Múltiple (REEM) Instituto de Salud Carlos III, Spain (RD07/0060/01, P.V.; RD12/0032/0002, A.S.; Marató de TV3 [20141830], F.G.) and Instituto de Salud Carlos III, Spain (CM14/00081; T.A.) 2016-04-14 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/10256/14251 http://hdl.handle.net/10256/14251 eng info:eu-repo/semantics/altIdentifier/doi/10.1212/NXI.0000000000000225 info:eu-repo/semantics/altIdentifier/eissn/2332-7812 Attribution-NonCommercial-NoDerivs 3.0 Spain http://creativecommons.org/licenses/by-nc-nd/3.0/es/ info:eu-repo/semantics/openAccess application/pdf Lippincott, Williams & Wilkins Neurology, Neuroimmunology and Neuroinflammation, 2016, vol. 3, núm 3, p. e225 Articles publicats (IdIBGi)